Lee S Cohen
Examiner (ID: 17427, Phone: (571)272-4763 , Office: P/3739 )
Most Active Art Unit | 3739 |
Art Unit(s) | 3739, 3305, 3794, 0, 3736, 3311 |
Total Applications | 3720 |
Issued Applications | 3004 |
Pending Applications | 173 |
Abandoned Applications | 543 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 17082100
[patent_doc_number] => 20210277106
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => ANTI-PACAP ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/202790
[patent_app_country] => US
[patent_app_date] => 2021-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56623
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17202790
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/202790 | ANTI-PACAP ANTIBODIES AND USES THEREOF | Mar 15, 2021 | Pending |
Array
(
[id] => 16913966
[patent_doc_number] => 20210187058
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => METHODS FOR ADMINISTERING ANGIOTENSIN II
[patent_app_type] => utility
[patent_app_number] => 17/192453
[patent_app_country] => US
[patent_app_date] => 2021-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15112
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17192453
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/192453 | Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II | Mar 3, 2021 | Issued |
Array
(
[id] => 17314503
[patent_doc_number] => 20210403551
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => APLNR Modulators and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/167990
[patent_app_country] => US
[patent_app_date] => 2021-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31651
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17167990
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/167990 | Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody | Feb 3, 2021 | Issued |
Array
(
[id] => 16871509
[patent_doc_number] => 20210164976
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => Methods of Treating Cardiovascular Diseases and Predicting the Efficacy of Exercise Therapy
[patent_app_type] => utility
[patent_app_number] => 17/167246
[patent_app_country] => US
[patent_app_date] => 2021-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13597
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17167246
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/167246 | Methods of Treating Cardiovascular Diseases and Predicting the Efficacy of Exercise Therapy | Feb 3, 2021 | Abandoned |
Array
(
[id] => 18491536
[patent_doc_number] => 11696941
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-11
[patent_title] => Compositions comprising a PCSK9 peptide conjugated to a qbeta carrier and methods of using the same
[patent_app_type] => utility
[patent_app_number] => 17/155549
[patent_app_country] => US
[patent_app_date] => 2021-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 21
[patent_no_of_words] => 17784
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 112
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17155549
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/155549 | Compositions comprising a PCSK9 peptide conjugated to a qbeta carrier and methods of using the same | Jan 21, 2021 | Issued |
Array
(
[id] => 16961568
[patent_doc_number] => 20210213067
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => METHODS FOR ENHANCING IMMUNOSUPPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/150457
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20189
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150457
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150457 | METHODS FOR ENHANCING IMMUNOSUPPRESSION | Jan 14, 2021 | Pending |
Array
(
[id] => 17005397
[patent_doc_number] => 20210236558
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => METHODS FOR INDUCING AN IMMUNE RESPONSE
[patent_app_type] => utility
[patent_app_number] => 17/150574
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20171
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150574
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150574 | Methods for inducing an immune response by administering activated mesenchymal stem cells | Jan 14, 2021 | Issued |
Array
(
[id] => 17022327
[patent_doc_number] => 20210246198
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-12
[patent_title] => METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/149540
[patent_app_country] => US
[patent_app_date] => 2021-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19660
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17149540
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/149540 | METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS | Jan 13, 2021 | Pending |
Array
(
[id] => 16962915
[patent_doc_number] => 20210214414
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => RECOMBINANT ROBO2 PROTEINS, COMPOSITIONS, METHODS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/125903
[patent_app_country] => US
[patent_app_date] => 2020-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32488
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17125903
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/125903 | Recombinant ROBO2 proteins, compositions, methods and uses thereof | Dec 16, 2020 | Abandoned |
Array
(
[id] => 19058991
[patent_doc_number] => 11938185
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-26
[patent_title] => Treatment of headache, migraine and/or photophobia conditions using humanized anti-PACAP antibodies
[patent_app_type] => utility
[patent_app_number] => 17/122243
[patent_app_country] => US
[patent_app_date] => 2020-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 58
[patent_figures_cnt] => 157
[patent_no_of_words] => 105251
[patent_no_of_claims] => 42
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 158
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17122243
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/122243 | Treatment of headache, migraine and/or photophobia conditions using humanized anti-PACAP antibodies | Dec 14, 2020 | Issued |
Array
(
[id] => 17170398
[patent_doc_number] => 20210324068
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => USE OF ANTI-PACAP ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF FOR TREATMENT, PREVENTION, OR INHIBITION OF PHOTOPHOBIA
[patent_app_type] => utility
[patent_app_number] => 16/953443
[patent_app_country] => US
[patent_app_date] => 2020-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 65861
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16953443
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/953443 | Screening method for identifying anti-PACAP antibodies or antibody fragments suitable for use in treating or preventing PACAP-associated photophobia or light aversion | Nov 19, 2020 | Issued |
Array
(
[id] => 17104386
[patent_doc_number] => 11124582
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-21
[patent_title] => FLT3L-FC fusion proteins
[patent_app_type] => utility
[patent_app_number] => 16/951458
[patent_app_country] => US
[patent_app_date] => 2020-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 34
[patent_no_of_words] => 92705
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951458
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/951458 | FLT3L-FC fusion proteins | Nov 17, 2020 | Issued |
Array
(
[id] => 18747091
[patent_doc_number] => 11806382
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-07
[patent_title] => Methods of inhibiting integrin a9b1 activity
[patent_app_type] => utility
[patent_app_number] => 16/951650
[patent_app_country] => US
[patent_app_date] => 2020-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 20
[patent_no_of_words] => 19340
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951650
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/951650 | Methods of inhibiting integrin a9b1 activity | Nov 17, 2020 | Issued |
Array
(
[id] => 17007105
[patent_doc_number] => 20210238266
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => COMPOSITIONS AND METHODS FOR ANTI-LYST IMMUNOMODULATION
[patent_app_type] => utility
[patent_app_number] => 17/098076
[patent_app_country] => US
[patent_app_date] => 2020-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20040
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17098076
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/098076 | COMPOSITIONS AND METHODS FOR ANTI-LYST IMMUNOMODULATION | Nov 12, 2020 | Pending |
Array
(
[id] => 17185232
[patent_doc_number] => 20210332117
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => METHODS FOR INHIBITING MYOSTATIN ACTIVATION BY ADMINISTERING ANTI-PRO/LATENT MYOSTATIN ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/083917
[patent_app_country] => US
[patent_app_date] => 2020-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68628
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17083917
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/083917 | Methods for altering body composition by administering anti-pro/latent myostatin antibodies | Oct 28, 2020 | Issued |
Array
(
[id] => 16657454
[patent_doc_number] => 20210054090
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/080626
[patent_app_country] => US
[patent_app_date] => 2020-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15291
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17080626
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/080626 | Antagonistic CD40 monoclonal antibodies and uses in treating immune responses | Oct 25, 2020 | Issued |
Array
(
[id] => 17214545
[patent_doc_number] => 20210347882
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => ANTIBODIES TO HUMAN RESISTIN
[patent_app_type] => utility
[patent_app_number] => 17/077433
[patent_app_country] => US
[patent_app_date] => 2020-10-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9812
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17077433
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/077433 | ANTIBODIES TO HUMAN RESISTIN | Oct 21, 2020 | Pending |
Array
(
[id] => 17126233
[patent_doc_number] => 20210301001
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => ANTIBODY THAT BINDS MURINE WISE PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/071931
[patent_app_country] => US
[patent_app_date] => 2020-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11209
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071931
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/071931 | ANTIBODY THAT BINDS MURINE WISE PROTEIN | Oct 14, 2020 | Abandoned |
Array
(
[id] => 16727890
[patent_doc_number] => 20210095037
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => METHODS FOR TREATING LATE-ONSET ASTHMA USING BENRALIZUMAB
[patent_app_type] => utility
[patent_app_number] => 17/031965
[patent_app_country] => US
[patent_app_date] => 2020-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9653
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17031965
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/031965 | METHODS FOR TREATING LATE-ONSET ASTHMA USING BENRALIZUMAB | Sep 24, 2020 | Pending |
Array
(
[id] => 16539452
[patent_doc_number] => 20200405865
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => ETANERCEPT FORMULATIONS STABILIZED WITH XYLITOL
[patent_app_type] => utility
[patent_app_number] => 17/019722
[patent_app_country] => US
[patent_app_date] => 2020-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9328
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17019722
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/019722 | ETANERCEPT FORMULATIONS STABILIZED WITH XYLITOL | Sep 13, 2020 | Abandoned |